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Abstract: 
Background: Family health history (FHH) is an underutilized tool in primary care to identify and 
risk-stratify individuals with increased cancer risk. Objective: Evaluate the influence of patient 
education on quantity and quality of FHH entered into a primary care-based software program, 
and impact on the program’s cancer risk management recommendations. Design: Two primary 
care practices within a larger type II hybrid implementation-effectiveness controlled clinical 
trial. Participants: English speaking non-adopted patients with a well visit appointment 
December 2012–March 2013. Interventions: One to two weeks prior to their well visit 
appointment, participants entered their FHH into the program. Participants were then provided 
educational materials describing key FHH components. They were instructed to use the interval 
to collect additional FHH information. Patients then returned for their scheduled appointment, 
and updated their FHH with any new information. Main Measures: Percentage per pedigree of 
relatives meeting individual quality criteria. Changes made after patient education and changes 
to recommendations for surveillance, chemoprevention or genetic counseling referral. Key 
Results: Post patient education, pedigrees exhibited a greater percentage (per pedigree) of: 
deceased relatives with age at death (84 vs. 81 % p = 0.02), deceased relatives with cause of 
death (91 vs. 87 % p = 0.02), relatives with a named health condition (45 vs. 42 %p = 0.002), 
and a greater percentage of relatives with high quality records (91 vs. 89 % p = 0.02). Of 43 
participants with pedigree changes that could trigger changes in risk stratified prevention 
recommendations, 12 participants (28 %) received such changes. Conclusions: Patient education 
improves FHH collection and subsequent risk stratification utilized in providing actionable 
evidence-based care recommendations for cancer risk management. 
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Article: 
Introduction 
Family health history (FHH) is an important component of patient care, facilitating risk 
stratification and application of evidence-based care for common diseases such as cancer, heart 
disease and diabetes [1–5]. FHH remains one of the strongest predictors of disease risk [6], has 
implications for other family members and is increasingly utilized in risk stratification for cancer 
surveillance (e.g. breast MRI), diagnostic testing, and/or genetic counseling referral [7–11]. 
Elements of FHH required in sufficient detail to yield meaningful risk stratification include: (1) 
three generations of relatives, (2) relatives’ lineage (e.g. maternal or paternal), (3) relatives’ 
gender, (4) up-to-date information, (5) pertinent negatives noted, (6) age of disease onset for 
affected relatives, and for deceased relatives (7) age of death, and (8) cause of death [12–15]. 
However, multiple barriers impede collection and accessibility of adequate FHH. These include: 
absence of reimbursement for time required to collect FHH [16]; lack of time secondary to 
competing clinical demands [17–21]; lack of training in gathering and interpreting FHH 
information [17]; and limitations in the patient’s knowledge of their own FHH [22]. While 
adoption of electronic medical records (EMRs) is anticipated to standardize and systematize 
collection, interpretation and presentation of patient data, EMRs do not effectively address these 
barriers, and may actually add to them [23]; Collectively, these barriers result in absent FHH or 
insufficient FHH to assess disease risk [24, 25]. 
To address this problem, Duke University, The University of North Carolina at Greensboro and 
Cone Health System collaborated to create the Genomedical Connection, and developed the 
genomic medicine model for primary care [26]. The model, described in detail elsewhere, 
integrates principles of the Health Belief Model and Adult Learning Theory to link education, 
FHH collection, patient activation, and clinical decision support in creating recommendations for 
FHH risk-stratified prevention strategies nested within primary care practice daily workflow. The 
model’s core delivery mechanism is a self-administered patient-facing software program, called 
MeTree. Briefly, MeTree gathers patient FHH on 48 diseases and provides real time risk 
stratification and clinical decision support for five pilot diseases: breast cancer, ovarian cancer, 
colon cancer, thrombophilia, and hereditary cancer syndromes. Upon completion, patients are 
given a copy of their pedigree and a “patient report” detailing salient aspects of their FHH for 
further discussion with their provider. Clinicians receive a copy of the pedigree, a tabular format 
of the FHH and a “provider report” detailing: actionable prevention and diagnostic strategies 
related to clinical decision support conditions; FHH elements triggering recommendations; and a 
summary of the risk stratification guidelines. Development and validation of MeTree is further 
described elsewhere [27]. A crucial component of MeTree’s effectiveness is adequate patient 
education. Evidence concerning patient education in collecting FHH is minimal, but existing 
evidence primarily examines education preceding genetic counseling referrals [28–31]. This 
paper describes the effect of patient education regarding FHH collection and risk stratification 
on: quantity and quality of FHH data collected and changes in resulting care recommendations. 
Methods 
Study design, participants and intervention 
This study was part of a larger type II hybrid implementation-effectiveness controlled clinical 
trial assessing the utilization and impact of MeTree in two community-based primary care 
practices in Greensboro, NC (referred to as the parent study for the purposes of this paper) [32]. 
In brief, all English speaking, non-adopted adult patients scheduled for a future well visit were 
contacted and invited to participate approximately 3 weeks before their scheduled visit. Patients 
who agreed to participate were consented and provided educational materials emphasizing why, 
what, and how to collect FHH by the study coordinator. Materials included a brochure (Online 
Resource 1) on why FHH and risk assessment is important for their own care, a booklet (Online 
Resource 2) on how to talk to their relatives and what information to collect (particularly the 
need to ask about age at onset, death status, and cause of death), and a worksheet (Online 
Resource 3) containing a list of diseases to ask about with a table to assist in documenting 
relatives’ conditions. On the day of appointment, patients self-entered their FHH into MeTree 
which then generated previously described patient and provider reports. 
In this sub-study, we evaluated the impact of patient education by inviting patients who met 
study criteria between December 2012 and March 2013 to complete MeTree prior to receiving 
the educational materials and provided an opportunity to revise their existing FHH afterwards. 
Patients who agreed to participate were consented and asked to self-enter their FHH into MeTree 
at a clinic kiosk prior to receiving any patient education (the pre-test). Upon completion of 
MeTree, participants were provided the educational materials, given 1–2 weeks to collect 
additional information (if desired), and return to update their existing FHH in MeTree with their 
newly acquired information at their scheduled well visit appointment (the post-test). Information 
in MeTree following the post-test was used to generate the clinical decision support for patient 
and provider reports. The study was approved by the IRB at each institution and the funder, US 
Army and Material Command. 
Data storage and outcomes measurement 
FHH pedigree data entered into MeTree for both pre-test and post-test was stored in a SQL 
database and analyzed using R statistical software [33]. Descriptive demographic information 
was recorded on each participant completing pre-test for comparison to participants in the parent 
study. Time to complete MeTree during the pre-test was also recorded for comparison with the 
parent study. Finally, all changes to the pedigree (e.g. additions, removals, death status) from 
initial pre-test to post-test and any changes to recommendations for additional screening, 
diagnostic tests or referrals to genetic counseling that would have been generated by the pre-test 
were recorded for subsequent analysis. 
Statistical analysis 
Following data collection we assessed baseline demographics of the sub-study and compared 
them to the parent study. Next we evaluated sub-study pedigrees before and after patient 
education describing types of changes, the percentage of sub-study making these changes and 
total number of changes for each type of change. Elements of a pedigree that contribute to a high 
quality FHH in generating appropriate risk stratified recommendations include: (1) three 
generations of relatives, (2) relatives’ lineage (e.g. maternal or paternal), (3) relatives’ gender, 
(4) up-to-date information, (5) pertinent negatives noted, (6) age of disease onset for affected 
relatives, and for deceased relatives (7) age of death, and (8) cause of death. The basic structure 
of MeTree meets the first 5 criteria automatically. High quality relatives were defined as 
relatives meeting one or more of the three non-automatic criteria described here. We assessed the 
remaining three individual elements required to define an adequate (high quality) FHH for risk 
stratification. For each pedigree this included the percentage of relatives with a condition who 
had an age at onset, the percentage of deceased relatives with an age at death, and the percentage 
of deceased relatives with a cause of death. We also assessed the percentage of relatives with a 
named health condition and total number of conditions reported in the pedigree. To examine 
change in completeness of FHH, we compared the average of these percentages (e.g. percent of 
deceased relatives with age at death) for all pedigrees before and after patient education. We then 
examined before and after pedigrees for changes in recommendations specific to breast cancer 
screening, colon cancer screening, and genetic counseling referral as an illustration of the impact 
of adequate FHH on risk stratified preventive screening actions. 
To assess for potential test-maturation bias, we selected a measure (change in number of 
siblings) which theoretically should not vary between pre and post pedigrees and evaluated for 
differences. Similarly, we selected a measure (number of relatives with colon polyp information) 
that should only vary with education and not as a function of completing the pedigree twice. 
Statistical tests performed in analysis included Chi Square Test (for categorical variables), 
Paired T Test (for continuous variables) and ANOVA (for comparisons between study sample 
and parent study). 
Results 
Characteristics of study sample 
One hundred consecutive participants were recruited and completed MeTree at enrollment. One 
did not return to update FHH and was therefore not included in analysis. Baseline demographics 
of the sub-study and parent study are detailed in Table 1. Participants in the sub-study were 
slightly more likely to be white and educated but were comparable to the parent study. The 
parent study population has been shown to be representative of the underlying clinic population 
[34]. Time to complete FHH prior to receiving education (sub-study) required an average of 6.6 
more minutes than in the parent study when it was completed after education. 
Table 1 Baseline characteristics of sub-study and parent study 
  Sub-study (n = 100) Parent study (n = 1,184) P value* 
No. (%) No. (%)   
Gender 
 Male 50 (50 %) 490 (41.4 %) 0.09 
Ethnicity 
 White 88 (88 %) 969 (81.8 %)   
 Black 9 (9 %) 159 (13.5 %) 0.12 
 Other 2 (2 %) 56 (4.7 %)   
Age 
 Mean (SD) 58.1 (11.4) 58.8 (11.8) 0.56 
 <50 21 (21 %) 250 (21.1 %)   
 50–65 47 (47 %) 575 (48.6 %) 0.98 
 >65 31 (31 %) 359 (30.3 %)   
Education 
 High school or less 10 (10 %) 158 (13.3 %) 0.35 
 Some college 17 (17 %) 245 (20.7 %)   
 College degree 42 (42 %) 461 (38.9 %)   
 Any graduate 30 (30 %) 320 (27.0 %)   
Minutes to complete MeTree 
 Mean (SD) 33.6 (19.1) 27 (12.23) <0.01 
* P value denotes two-sample test comparing proportion (or mean) for inequality between sub-
study and parent-study 
Illustrative pedigree pre and post 
An illustrative example of a participant pedigree before education and revised after patient 
education demonstrating typical pedigree changes is shown in Fig. 1. Grey quadrants represent 
revisions in the post pedigree with numbers indicating the quantity of changes. The upper left 
quadrant represents a change in disease status with potential impact on care recommendations, 
while the upper right quadrant represents change in age of onset for a disease with potential 
impact on care recommendations. Changes in lower left and lower right quadrants represent 
changes in disease status and age of onset that do not impact care recommendations for the pilot 
conditions. 
 
Fig. 1 MeTree pedigree before and after education. This example pedigree illustrates changes to 
a pedigree after patient education. Squares are male relatives, circles are female relatives, 
a diagonal line corresponds to a deceased relative and a dashed line represents a relative for 
whom no data is available. Shaded quadrants represent a change in the post education pedigree 
with the number in the quadrant corresponding to the number of changes in that category. 
The upper left quadrant is a change in disease status; the upper right quadrant is a change in the 
age of onset of a disease. Both upper quadrants represent changes that influence a care 
recommendation. The lower left quadrant corresponds to a change in disease status not affecting 
recommendations, while the lower right quadrant represents a change in age of onset not 
affecting recommendations. The diagonal black arrow represents the proband 
Test-maturation bias 
To investigate potential repeated testing bias (participants may perform better on second MeTree 
session due only to familiarity with MeTree) associated with two or more MeTree sessions, we 
examined the change in number of siblings reported before and after patient education for each 
pedigree. We hypothesized this number should not change as a function of education, and would 
only change as a function of application familiarity. We found no changes in number of siblings 
for any pedigree between pre and post MeTree sessions. Similarly, we sought to examine an 
attribute of the pedigree that should only change with patient education, to compare sub-study 
post session with the parent study. In the absence of any test-maturation bias, the attribute should 
be comparable between the sub-study and parent study, as both received patient education before 
a MeTree session. We found no difference in number of relatives with colon polyps entered into 
the pedigree between sub-study and parent study (mean 0.51 vs. 0.59 relatives p = 0.42). 
Changes to FHH following receipt of patient education 
Participants completing a revised pedigree after receiving patient education (post-test) made 
several types of changes to their initial (pre-test) pedigree. These changes are illustrated in 
Fig. 2 and include: adding or removing a relative; changing, adding, or removing the age of a 
relative (includes age of death if relative deceased); changing Alive/Deceased status of a relative; 
changing cause of death for a deceased relative; changing, adding, or removing diseases for a 
relative; and changing, adding or removing age of disease onset. Half of the participants made 
changes to their pedigree following education. The most common changes were for disease 
status (42 %), age (27 %) and age of disease onset (18 %). Among those that made any change to 
relatives in their pedigree, the average number of changes per pedigree was 8.41 (SD = 6.72). 
Similarly, among those that made any change to a relative’s disease status in their pedigree, the 
average number of relatives with a disease status change per pedigree was 4.62 (SD = 3.48). A 
total of 412 relatives had any change, while 194 had a disease change and 208 had an age change 
(current age, age of onset, age at death). 
 
Fig. 2 Types of pedigree changes after patient education. The bar graph represents the percent of 
the study sample pedigrees with specific types of changes. Nearly half of the pedigrees (n = 49) 
had some change after patient education. Numbers below represent mean (and SD) number of 
changes per pedigree of affected pedigrees in each category and total number of relative changes 
in each category. For example, 49 pedigrees had any changes resulting in a mean of 
8.41(SD = 6.72) changes per pedigree among pedigrees with any changes and a total of 412 
relatives with changes 
Changes in elements of pedigree contributing to high quality FHH 
As previously described in Methods, MeTree automatically meets 5 of 8 criteria for a high 
quality pedigree. We examined the remaining three criteria. For each pedigree, a percentage of 
eligible relatives satisfying each criterion was calculated and then averaged to describe the mean 
percentage before and after receiving education (Table 2). In general, the average percentage of 
eligible relatives satisfying the criterion increased following education. In addition, the 
completeness of disease documentation improved as indicated by the increase in the percentage 
of relatives per pedigree (42 vs. 45 % p = 0.002) with a named health condition, an increase in 
the number of conditions per pedigree (18.9 vs. 20.5 p < 0.001) and by the decrease in the 
percentage of relatives per pedigree (9 % vs. 6 % p = 0.01) with no data entered (relatives with 
no diseases, age, or alive/dead status reported). These changes yielded an increase in the 
percentage of relatives that were considered high quality (meeting 1 or more of the 3 non-
automatic criteria if eligible) between pre and post-test (89 vs. 91 % p = 0.02). The impact of this 
is shown in Fig. 3, which represents the overall increase in the percentage of relatives per 
pedigree meeting high quality criteria following patient education. This effect is most 
pronounced when 80 % or more of the relatives in the pedigree are required to meet all 8 criteria 
for the pedigree to be considered high-quality. 
Table 2 Percentage of family health history elements present before/after education 
Characteristic Before After P value* 
Dead relatives who have age at death 81 % 84 % 0.02 
Dead relatives with cause of death 87 % 91 % 0.02 
Relatives who have age at onset 48 % 50 % 0.2 
Relatives with some condition 42 % 45 % <0.01 
Relatives with no data 9 % 6 % 0.01 
Number of conditions reported, mean (SD) 18.9 (11.0) 20.5 (11.7) <0.01 
High quality relatives in pedigree 89 % 91 % 0.02 
For each pedigree, a percentage of eligible relatives satisfying each element was calculated. 
Numbers above represent an average of pedigree percentages before and after patient education 
* p value determined using Paired T test 
 
Fig. 3 Proportion of high-quality pedigrees versus proportion of high-quality relatives required. 
The figure illustrates the diminishing proportion of pedigrees that meet high-quality criteria as 
the proportion of high-quality relatives, those meeting all 8 criteria, required increases. 
The horizontal axis is the proportion of high-quality relatives required for the pedigree to be 
considered high-quality. The vertical axis is the proportion of pedigrees that are considered high 
quality. The post education pedigree demonstrates a greater proportion of pedigrees that are 
considered high-quality, with a pronounced effect above a 0.8 threshold 
Changes in risk stratified care recommendations for pilot conditions 
Because of the way risk is assessed in preventive care guidelines for clinical decision support 
conditions (breast, ovarian, and colon cancer, hereditary cancer syndromes, and thrombosis), 
pedigree changes that could trigger a change in risk stratified preventive care recommendations 
were disease status and change in age of disease onset. Among 99 participants, 42 % made 
changes to disease status and 18 % to age of disease onset. Combined, 43 participants made a 
change in at least one of these two criteria resulting in 43 % with a potential recommendation 
change. Of these, 12 of 43 (28 %) participants received recommendation changes. See 
Table 3 for details regarding which recommendations were changed and how frequently. 
Specifically, 4 received new recommendations to undergo genetic counseling, and 6 received 
new recommendations for colon cancer screening. 
Table 3 Changes in genetic counseling or screening recommendations (Pre → Post) 
Recommendation Yes → No No → Yes Total number of post “Yes” Recs
Breast cancer screening rec* 0 0 2 
Colon cancer screening rec 4 6 30 
Genetic counseling rec 2 4 24 
Total changes 6 10   
* rec recommendation. There were two pedigrees with a recommendation for breast MRI that 
did not change from pre-test to post-test. Four pre-test recommendations for colon cancer 
screening were removed at post-test while six of the total recommendations for screening at post-
test (20 %) would have been missed by pre-test alone 
Discussion 
FHH, one of the strongest predictors of disease risk, is an important component of patient care 
that facilitates risk stratification for non-routine screening procedures, diagnostic testing and 
referral to genetic counseling in multiple common diseases. Yet, absent or insufficient 
reimbursement, competing clinical demands, inadequate training in gathering/interpreting FHH, 
and limited patient knowledge of their FHH mitigate its full potential in patient care delivery. 
Using a previously developed and validated patient facing software application, we sought to 
examine the influence of patient education on the quantity of data entered, the quality of the 
FHH generated (which affects the ability to perform risk stratification), and its impact on the risk 
stratified screening recommendations the patient met criteria for. 
We found a substantial number of changes between pre and post education pedigrees. The types 
of changes were varied and included changes in diseases as well as age of onset which are 
critical in generating risk stratified recommendations. We also noted improvements in multiple 
elements of FHH required for adequate risk stratification and a significant overall increase in the 
percentage of relatives in each pedigree meeting high quality criteria for risk stratification. In 
addition, patients did obtain and review their own medical files in order to update their personal 
history in MeTree. Together, these findings may indicate a willingness on patients’ part to 
become more active members in their healthcare by seeking additional information and 
consulting with others when needed; particularly when they are made aware of the endeavor’s 
importance and how to accomplish it effectively. This is an important step towards meeting the 
goals of shared decision making and patient activation. 
Remarkably, more than a quarter of the changes that could potentially change recommendations 
resulted in actual changes to recommendations for genetic counseling referral or surveillance. 
Collectively, these results suggest that receipt of patient education regarding who, how, and what 
to collect when obtaining FHH yields a clinically meaningful difference in the provision of care 
for patients. Furthermore, patient education enhances the adequacy of FHH, increasing the 
accuracy of clinical decision support and appropriate care recommendations. We liken an 
inadequate FHH to performing a diagnostic test only to receive indeterminate results. Patient 
education reduces the percentage of indeterminate results in using FHH. 
This study is limited in several aspects. First, the sample size was limited to 100 participants with 
follow up data for 99 participants. While the sample exhibited comparable demographics to the 
parent study and the larger clinic population, we could not eliminate the potential for 
unmeasured differences in the study sample which may have contributed to differences in the pre 
and post MeTree sessions. We also acknowledge that this sub-study and the parent study 
population may be more educated than the national population, potentially limiting 
generalizability of our results. Second, the study did not include a traditional control group with 
patients who did not receive any education. To address the possibility of the potential for test-
maturation bias, we examined this issue further in secondary analysis of attributes that should not 
change with testing (number of siblings) and with attributes that should only change with patient 
education (number of relatives with number of polyps data). These results suggest changes are 
secondary to patient education and not due to a second exposure to MeTree. However, alone they 
cannot be considered confirmatory. Finally, although MeTree collects FHH for 48 diseases, real-
time clinical decision support was only active for five pilot conditions. As a greater number of 
conditions are activated with clinical decision support, we would anticipate the number of 
changes seen in the pedigrees to result in a greater influence on additional risk stratified 
screening and testing. 
In conclusion, patient education significantly improves FHH collection and subsequent risk 
stratification. Patient education yields important changes in actionable evidence-based care 
recommendations. It may also serve to activate patients and make them partners in their own 
healthcare. Thus, patient education concerning FHH is imperative regardless of the method 
utilized to collect it. However, the combination of patient education and a patient facing FHH 
collection tool optimize the wealth of clinical information utilized in providing non-routine 
screening procedures, diagnostic testing, and referral to genetic counseling for multiple common 
diseases. Take-home educational materials and a patient self-administered software application 
maximally leverage the generalist’s resources in discussing recommendations within multiple 
complex competing clinical demands encountered during care delivery. 
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